Altre lingue IQ-AI Limited

Azioni

Mercato chiuso - London S.E. Altri mercati azionari 17:35:22 02/05/2024			Variaz. 5gg	Var. 1 gen.
1,7 ^GBX	+6,25%		+9,68%	-63,83%

16:46	GUADAGNI E TRADING: Trident Royalties passa all'utile	AN
29/04	IQ-AI Limited fornisce una guida alle entrate per l'anno finanziario 2024	CI

EARNINGS AND TRADING: Trident Royalties swings to profit	16:46
IQ-AI Limited Provides Revenue Guidance for the Financial Year 2024	29/04
IQ-AI Limited Reports Earnings Results for the Full Year Ended December 31, 2023	29/04
IQ-AI advances glioblastoma clinical trial, eyes phase two in 2025	26/02
IQ-AI's Broker Exercises Option to Buy Shares in Placing	26/02
IQ-AI Plans Share Placing to Advance Oral Anti-tumor Agent Development	22/02
IQ-AI shares sink on discounted placing fundraise	22/02
IQ-AI Unit to Revise, Resubmit Pediatric Rare Disease Designation Application After US FDA Feedback	09/02
IQ-AI subsidiary asked by FDA to resubmit and modify application	09/02
IQ-AI Unit Secures Grant for Brain Tumor Pill Access Program	02/02
IQ-AI celebrates USD100,000 grant for subsidiary	02/02
IQ-AI falls after subsidiary notes launch of treatment access scheme	10/01
IQ-AI's Imaging Biometrics Plans Expanded Access Program for Brain Tumor Treatment	10/01
IQ-AI Subsidiary’s Glioblastoma Therapy Obtains Fast-Track Designation From US FDA	19/12
IQ-AI firm gets US FDA fast-track status for oral gallium maltolate	19/12
IQ-AI's Imaging Biometrics Discloses Positive Results in Early-stage Study of Potential Brain Cancer Treatment	05/12
IQ-AI stock rises on positive interim results from glioblastoma trial	05/12
IQ-AI Unit Seeks Pediatric Rare Disease Designation for Brain Tumor Treatment	08/11
IQ-AI says Imaging Biometrics submits paediatric rare disease request	08/11
IQ-AI Applies for FDA Pediatric Rare Disease Designation	08/11

Non ci sono risultati per questa ricerca